SSKN STRATA Skin Sciences, Inc. Insider Trading

Director Rubinstein sells 14,094 shares (50.9% of holdings) over two days at $1.32–$1.36, then buys 5,000 shares at $1.40–$1.41

Rubinstein executed 3 separate sales totaling 14,094 shares for $18,803.84 on November 17, reducing his holdings by 50.9%, followed by purchases of 5,000 shares for $7,028.32 on November 18 at slightly higher prices. The timing of these paired transactions—large liquidation immediately followed by smaller acquisition—coincides with stock weakness; SSKN has declined 27.0% over 30 days and 58.8% from its 52-week high of $3.35. The company is unprofitable with net income of $-1,622,000.00 in the latest quarter and minimal growth (0.6% annual revenue growth). The net effect is a substantial reduction in Rubinstein's stake from 17,860 to 8,766 shares, suggesting a material shift in exposure to the company despite the modest reacquisition on the following day.

CEO Rafaeli Dolev buys 19,100 shares at $3.14 amid stock decline of 69.0% from 52-week high; CEO and 2 other insiders buying within 14 days

Rafaeli Dolev (CEO) purchased 19,100 shares for $59,974.00 on 2024-07-15, increasing his holdings to 143,156 shares—a 15.4% increase in post-transaction shares. This transaction occurs within a 14-day cluster in which 2 other insiders also bought shares, suggesting coordinated confidence despite current market conditions. The company is unprofitable with net income of $-3,368,000.00 in its latest quarter and -7.8% annual revenue growth, trading at $3.10—down 69.0% from its $10.00 52-week high and down 41.8% over 90 days. The CEO's discretionary purchase at a significantly depressed price point during a multi-insider buying cluster warrants attention to whether this reflects conviction or signals underlying business concerns the market is not yet pricing in.

10% owner Accelmed Partners acquires 230,573 shares of SSKN at $3.14; 2 other insiders also bought in 14-day cluster amid -41.8% 90-day decline

Accelmed Partners, a 10% owner, purchased 230,573 shares at $3.14 on 2024-07-15, expanding holdings by 19.0% to 1,441,835 shares total. The timing coincides with a cluster pattern: 2 other insiders also bought within the past 14 days. This coordinated accumulation occurred as SSKN's stock has declined 41.8% over the past 90 days and 69.0% from its 52-week high of $10.00, creating a contrarian signal. The company is unprofitable (net income of -$3,368,000 in the latest quarter, negative full-year results) and experiencing revenue headwinds (-7.8% annual growth), so the cluster buy against weak fundamentals and steep price declines warrants investor scrutiny of the insiders' informational advantage or strategic positioning.

Director Geiger Uri buys 230,573 shares at $3.14 amid cluster pattern; stock down -69.0% from 52-week high and company unprofitable.

Director Geiger Uri purchased 230,573 shares at $3.14 on 2024-07-15, increasing holdings by 19.0% to 1,441,835 shares total, valued at $723,999.22. This buy occurred as part of a cluster pattern with 2 other insiders also purchasing within the past 14 days. The transaction takes place against a backdrop of significant stock deterioration: the stock currently trades at $3.10, down -69.0% from its 52-week high of $10.00 and down -41.8% over the past 90 days. Fundamentally, SSKN reported quarterly revenue of $6,754,000.00 with a net loss of $-3,368,000.00, annual revenue declined -7.8% year-over-year, and the company was unprofitable over its most recent full fiscal year. The convergence of multiple insider purchases during a sharp drawdown, combined with persistent operating losses and revenue contraction, warrants investor scrutiny of the underlying drivers motivating this cluster buy activity.